Abstract
Recent work on the pathogenesis of type 1 diabetes has led to an evolving recognition of the heterogeneity of this disease, both with regards to clinical phenotype and responses to therapies to prevent or revert diabetes. This heterogeneity not only limits efforts to accurately predict clinical disease but also is reflected in differing responses to immunomodulatory therapeutics. Thus, there is a need for robust biomarkers of beta cell health, which could provide insight into pathophysiological differences in disease course, improve disease prediction, increase the understanding of therapeutic responses to immunomodulatory interventions and identify individuals most likely to benefit from these therapies. In this review, we outline current literature, limitations and future directions for promising circulating markers of beta cell stress and death in type 1 diabetes, including markers indicating abnormal prohormone processing, circulating RNAs and circulating DNAs.
| Original language | English (US) |
|---|---|
| Journal | Diabetologia |
| DOIs | |
| State | Accepted/In press - Jan 1 2018 |
Fingerprint
Keywords
- Biomarker
- Diabetes mellitus
- Pancreatic beta cells
- Pancreatic islets
- Review
- Type 1 diabetes
ASJC Scopus subject areas
- Internal Medicine
- Endocrinology, Diabetes and Metabolism
Cite this
Biomarkers of islet beta cell stress and death in type 1 diabetes. / Sims, Emily K.; Evans-Molina, Carmella; Tersey, Sarah A.; Eizirik, Decio L.; Mirmira, Raghu.
In: Diabetologia, 01.01.2018.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Biomarkers of islet beta cell stress and death in type 1 diabetes
AU - Sims, Emily K.
AU - Evans-Molina, Carmella
AU - Tersey, Sarah A.
AU - Eizirik, Decio L.
AU - Mirmira, Raghu
PY - 2018/1/1
Y1 - 2018/1/1
N2 - Recent work on the pathogenesis of type 1 diabetes has led to an evolving recognition of the heterogeneity of this disease, both with regards to clinical phenotype and responses to therapies to prevent or revert diabetes. This heterogeneity not only limits efforts to accurately predict clinical disease but also is reflected in differing responses to immunomodulatory therapeutics. Thus, there is a need for robust biomarkers of beta cell health, which could provide insight into pathophysiological differences in disease course, improve disease prediction, increase the understanding of therapeutic responses to immunomodulatory interventions and identify individuals most likely to benefit from these therapies. In this review, we outline current literature, limitations and future directions for promising circulating markers of beta cell stress and death in type 1 diabetes, including markers indicating abnormal prohormone processing, circulating RNAs and circulating DNAs.
AB - Recent work on the pathogenesis of type 1 diabetes has led to an evolving recognition of the heterogeneity of this disease, both with regards to clinical phenotype and responses to therapies to prevent or revert diabetes. This heterogeneity not only limits efforts to accurately predict clinical disease but also is reflected in differing responses to immunomodulatory therapeutics. Thus, there is a need for robust biomarkers of beta cell health, which could provide insight into pathophysiological differences in disease course, improve disease prediction, increase the understanding of therapeutic responses to immunomodulatory interventions and identify individuals most likely to benefit from these therapies. In this review, we outline current literature, limitations and future directions for promising circulating markers of beta cell stress and death in type 1 diabetes, including markers indicating abnormal prohormone processing, circulating RNAs and circulating DNAs.
KW - Biomarker
KW - Diabetes mellitus
KW - Pancreatic beta cells
KW - Pancreatic islets
KW - Review
KW - Type 1 diabetes
UR - http://www.scopus.com/inward/record.url?scp=85051635227&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85051635227&partnerID=8YFLogxK
U2 - 10.1007/s00125-018-4712-1
DO - 10.1007/s00125-018-4712-1
M3 - Article
C2 - 30112687
AN - SCOPUS:85051635227
JO - Diabetologia
JF - Diabetologia
SN - 0012-186X
ER -